AstraZeneca PLC (NASDAQ:AZN)
| 60.20 Delayed Data As of Jan 20 |  +0.69 / +1.16%Today’s Change | 46.48 Today|||52-Week Range 64.21 | +3.35% Year-to-Date |
Latest AZN News | Press Releases
| Is Ocugen Stock a Buy Now? Jan 20 / MotleyFool.com - Paid Partner Content | Here's Some Good News for Novavax That Investors Are Overlooking Jan 18 / MotleyFool.com - Paid Partner Content |
| Valneva (VALN) Up as COVID-19 Jab Neutralizes Omicron Variant Jan 20 / Zacks.com - Paid Partner Content | This Could Be Another Blockbuster Indication for AstraZeneca Jan 17 / MotleyFool.com - Paid Partner Content |
| 3 Under-the-Radar COVID Stocks Jan 19 / MotleyFool.com - Paid Partner Content | 2 Risky Growth Stocks That Could Make You Filthy Rich Jan 16 / MotleyFool.com - Paid Partner Content |
| Will Moderna (MRNA) Continue to Ride on Vaccine Sales in 2022? Jan 18 / Zacks.com - Paid Partner Content | AstraZeneca (AZN) COVID-19 Booster Dose Useful Against Omicron Jan 14 / Zacks.com - Paid Partner Content |
| AstraZeneca (AZN) Enhertu sBLA Receives FDA Priority Tag Jan 18 / Zacks.com - Paid Partner Content | 1 Top Dividend Stock to Buy and Hold in 2022 and Beyond Jan 13 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 59.48 |
| Today’s open | 60.20 |
| Day’s range | 59.84 - 60.62 |
| Volume | 6,171,965 |
| Average volume (3 months) | 5,048,068 |
| Market cap | $182.4B |
Data as of 4:00pm ET, 01/20/2022
Growth & Valuation
| Earnings growth (last year) | +137.38% |
| Earnings growth (this year) | +29.50% |
| Earnings growth (next 5 years) | +19.67% |
| Revenue growth (last year) | +13.16% |
| P/E ratio | 108.5 |
| Price/Sales | 4.76 |
| Price/Book | 9.89 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NVSNovartis | -0.09 | -0.10% |
| MRKMerck | -0.22 | -0.27% |
| NVONovo Nordisk | -0.05 | -0.05% |
| BMYBristol-Myers Squibb | -0.15 | -0.23% |
Data as of 5:08pm ET, 01/20/2022
Financials
| Next reporting date | February 10, 2022 |
| EPS forecast (this quarter) | $0.77 |
| Annual revenue (last year) | $27.6B |
| Annual profit (last year) | $3.2B |
| Net profit margin | 11.58% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Cambridge, Cambridgeshire |
Forecasts
